NASDAQ:PROK ProKidney (PROK) Stock Forecast, Price & News $4.32 0.00 (0.00%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$3.95▼$4.3450-Day Range$4.32▼$13.0852-Week Range$3.95▼$14.19Volume726,426 shsAverage Volume290,645 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$15.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ProKidney MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside261.1% Upside$15.60 Price TargetShort InterestBearish38.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 5 Articles This WeekInsider TradingSelling Shares$9.30 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.20) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.67 out of 5 starsMedical Sector872nd out of 976 stocksBiological Products, Except Diagnostic Industry145th out of 159 stocks 3.4 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.60, ProKidney has a forecasted upside of 261.1% from its current price of $4.32.Amount of Analyst CoverageProKidney has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted38.47% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 21.2, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 2.3 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ProKidney this week, compared to 1 article on an average week.Search Interest6 people have searched for PROK on MarketBeat in the last 30 days. MarketBeat FollowsOnly 5 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,299,000.00 in company stock.Percentage Held by Insiders44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.94% of the stock of ProKidney is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($1.20) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ProKidney (NASDAQ:PROK) StockProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comProKidney (NASDAQ:PROK) Sees Unusually-High Trading VolumeSeptember 23, 2023 | americanbankingnews.comChamath Palihapitiya Sells 1,700,000 Shares of ProKidney Corp. (NASDAQ:PROK) StockSeptember 28, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 22, 2023 | benzinga.comProKidney 10% Owner Trades $9.30M In Company StockSeptember 13, 2023 | seekingalpha.comREACT Or Retreat: ProKidney's Phase 3 Focal PointSeptember 6, 2023 | finance.yahoo.comProKidney confirms it will expand HQ complex, add 50 jobs in Winston-SalemSeptember 5, 2023 | finance.yahoo.comProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare ConferenceAugust 31, 2023 | bizjournals.comProKidney gets Forsyth County's OK for incentives to expand HQ in Winston-SalemSeptember 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 29, 2023 | finance.yahoo.comProKidney confirmed as company seeking incentives to expand in Forsyth CountyAugust 15, 2023 | bizjournals.comNearly 330 jobs tied to pair of incentives sought by two companies in Winston-SalemAugust 11, 2023 | finance.yahoo.comProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansionAugust 11, 2023 | finance.yahoo.comProKidney Reports Second Quarter Financial Results and Recent Corporate HighlightsJuly 26, 2023 | msn.comBTIG Initiates Coverage of ProKidney Corp - (PROK) with Buy RecommendationJuly 18, 2023 | bizjournals.comProKidney closes on Greensboro site for commercializationJuly 18, 2023 | finance.yahoo.comProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NCJuly 17, 2023 | bizjournals.comProKidney appoints Dr. Bruce Culleton as executive VP of clinical development and commercializationJuly 17, 2023 | finance.yahoo.comProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and CommercializationJuly 12, 2023 | bizjournals.comQ&A with Greensboro's Marvin Price, the NC economic developer of the yearJuly 4, 2023 | benzinga.comBoard Member at ProKidney Acquires Company Stock Options Worth 48,128 SharesJuly 3, 2023 | benzinga.comProKidney Board Member Awarded $537K Worth of Stock OptionsJuly 3, 2023 | benzinga.comProKidney Director Awarded $537K Worth of Stock OptionsJune 14, 2023 | bizjournals.comProKidney manufacturing: The one that didn't get awayJune 14, 2023 | news.yahoo.comMajor biomanufacturing project slated for TriadJune 14, 2023 | bizjournals.comProKidney wins North Carolina incentives for $458M, 330-job manufacturing plant in GreensboroJune 14, 2023 | bizjournals.comProKidney wins NC incentives, plans $458M manufacturing facility with 330 jobs in GreensboroJune 13, 2023 | msn.comBiomanufacturing facility aiming to treat chronic kidney disease coming to Guilford CountySee More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Company Calendar Last Earnings8/10/2023Today9/28/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.60 High Stock Price Forecast$18.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+261.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,030,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-7.33% Debt Debt-to-Equity RatioN/A Current Ratio19.04 Quick Ratio19.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($42.77) per share Price / Book-0.10Miscellaneous Outstanding Shares235,130,000Free Float129,344,000Market Cap$1.02 billion OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Timothy A. Bertram D.V.M. (Age 68)Ph.D., Founder, CEO & Director Comp: $970.4kDr. Deepak Jain Ph.D. (Age 69)Chief Operating Officer Comp: $768.65kMr. Todd C. Girolamo Esq. (Age 58)J.D., M.B.A., Chief Legal Officer & Corp. Sec. Comp: $600.17kMr. James Coulston CPA (Age 47)Chief Financial Officer Dr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., Sr. VP of Investor RelationsMs. Mary Weger (Age 64)Chief People Officer Ms. Ashley H. JohnsSr. VP & Head of Global Clinical OperationsDr. Joseph M. Stavas M.D.M.P.H., Sr. VP and Head of Global Clinical Devel. & Interventional ProceduresDr. Darin J. Weber Ph.D. (Age 55)Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access Dr. Bruce Culleton M.D.Exec. VP of Clinical Devel. & CommercializationMore ExecutivesKey CompetitorsRelay TherapeuticsNASDAQ:RLAYPrime MedicineNYSE:PRMEApogee TherapeuticsNASDAQ:APGEReplimune GroupNASDAQ:REPLIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsChamath PalihapitiyaSold 1,700,000 sharesTotal: $9.30 M ($5.47/share)California State Teachers Retirement SystemBought 20,560 shares on 8/21/2023Ownership: 0.020%Nuveen Asset Management LLCBought 210,892 shares on 8/16/2023Ownership: 0.090%Royal Bank of CanadaBought 5,860 shares on 8/15/2023Ownership: 0.003%Lazard Asset Management LLCBought 2,777 shares on 8/15/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions PROK Stock - Frequently Asked Questions Should I buy or sell ProKidney stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PROK shares. View PROK analyst ratings or view top-rated stocks. What is ProKidney's stock price forecast for 2023? 5 Wall Street analysts have issued 1 year price targets for ProKidney's shares. Their PROK share price forecasts range from $13.00 to $18.00. On average, they anticipate the company's share price to reach $15.60 in the next year. This suggests a possible upside of 261.1% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts. How have PROK shares performed in 2023? ProKidney's stock was trading at $6.86 at the beginning of the year. Since then, PROK shares have decreased by 37.0% and is now trading at $4.32. View the best growth stocks for 2023 here. When is ProKidney's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our PROK earnings forecast. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.27. What ETF holds ProKidney's stock ? ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio. What is ProKidney's stock symbol? ProKidney trades on the NASDAQ under the ticker symbol "PROK." Who are ProKidney's major shareholders? ProKidney's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.41%), State Street Corp (0.42%), Geode Capital Management LLC (0.32%), Northern Trust Corp (0.19%), Nuveen Asset Management LLC (0.09%) and Nuveen Asset Management LLC (0.09%). View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProKidney's stock price today? One share of PROK stock can currently be purchased for approximately $4.32. How much money does ProKidney make? ProKidney (NASDAQ:PROK) has a market capitalization of $1.02 billion. The company earns $-108,030,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. How can I contact ProKidney? ProKidney's mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The official website for the company is www.prokidney.com. The company can be reached via phone at 336-999-7028 or via email at lroth@burnsmc.com. This page (NASDAQ:PROK) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.